GlassScriptPhysician profile
Mason Tootell
NPI 1568675270
$6,434.76
in general payments reported to CMS, 2019-2025
36 companies · $683 in 2025
The $683 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,267 · 2020: $1,139 · 2021: $1,215 · 2022: $991 · 2023: $628 · 2024: $512 · 2025: $683.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,823.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,823.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $828.90 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $752.00 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $548.78 | 2019-2024 | Stiolto Respimat, Spiriva Respimat |
| Lilly USA, LLC | $453.11 | 2019-2025 | Mounjaro, Jardiance, Trulicity |
| Glaxosmithkline, LLC. | $446.37 | 2019-2023 | Shingrix, Arexvy, Bexsero |
| Merck Sharp & Dohme LLC | $362.97 | 2019-2023 | Verquvo, Belsomra |
| Novo Nordisk INC | $359.13 | 2019-2025 | Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $320.91 | 2022-2025 | |
| Amarin Pharma, INC. | $316.38 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $230.89 | 2019-2022 | |
| Boston Scientific Corporation | $204.17 | 2023-2025 | Watchman Access System, Watchman Flx |
| Abbvie INC. | $167.04 | 2021-2025 | Vraylar |
| Amgen INC. | $162.78 | 2019-2025 | Repatha, Evenity, Prolia |
| E.R. Squibb & Sons, L.L.C. | $157.13 | 2021-2023 | Eliquis, Camzyos |
| Exact Sciences Corporation | $142.46 | 2023-2025 | Cologuard Collection Kit |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $98.92 | 2019-2024 | Veozah |
| Sunovion Pharmaceuticals INC. | $84.22 | 2021 | |
| Abbott Laboratories | $75.57 | 2022-2025 | Freestyle Libre 3 |
| Biohaven Pharmaceutical Holding Company LTD. | $74.77 | 2022 | |
| Sanofi-Aventis U.S. LLC | $63.22 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $60.26 | 2021 | |
| Collegium Pharmaceutical, INC. | $59.05 | 2022-2023 | Xtampza, Belbuca |
| Radius Health, INC. | $55.18 | 2024-2025 | Tymlos |
| Kci USA, INC. | $52.00 | 2019 | |
| Grifols USA, LLC | $48.82 | 2020 | |
| Phathom Pharmaceuticals, INC. | $43.39 | 2024-2025 | Voquezna |
| Verona Pharma, INC. | $38.98 | 2025 | Ohtuvayre |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $35.51 | 2025 | Caplyta |
| Xeris Pharmaceuticals, INC. | $29.60 | 2021-2024 | Gvoke Hypopen |
| Teva Pharmaceuticals USA, INC. | $29.40 | 2021 | |
| Nestle Healthcare Nutrition INC. | $28.32 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $23.28 | 2021 | |
| Almatica Pharma LLC | $21.38 | 2022 | |
| Alkermes, INC. | $21.15 | 2019 | |
| Mylan Specialty L.P. | $20.96 | 2022 | |
| Novartis Pharmaceuticals Corporation | $17.76 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mason Tootell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.